Aggregation state-dependent activation of the classical complement pathway by the amyloid β peptide

Journal of Neurochemistry

Volumn 69, Issue 1, 1997, Pages 388-398

  Webster, Scott ^a   Bradt, Bonnie ^b   Rogers, Joseph ^a   Cooper, Neil ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aggregation; Amyloid peptide fibrils; C3; C4; Complement activation; Thioflavin T

Indexed keywords

AMYLOID BETA PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C4; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; COMPLEMENT ACTIVATION; NERVE CELL LESION; PRIORITY JOURNAL; PROTEIN AGGREGATION;

EID: 0030918418     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69010388.x     Document Type: Article

References (63)

1. Abbas A. K., Lichtman A. H., and Pober J. S. (1991) Cellular and Molecular Immunology, pp. 259-282. WB Saunders, Philadelphia.
2. Arispe N., Pollard H. B., and Rojas E. (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AβP-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. USA 90, 10573-10577.
3. Brachova L., Lue L.-F., Schultz J., El Rashidy T., and Rogers J. (1993) Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol. Brain Res. 18, 329-334.
4. Bunse R. and Heinz H.-P. (1993) Interaction of the capsular polysaccharide of Haemophilus influenzae type B with C1q. Behring Inst. Mitt. 93, 148-164.
5. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267, 546-554.
6. Butterfield A. D., Hensley K., Harris M., Mattson M., and Carney J. (1994) β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200, 710-715.
7. Castano E. M., Ghiso J., Prelli F., Gorevic P. D., Migheli A., and Frangione B. (1986) In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem. Biophys. Res. Commun. 141, 782-789.
8. Chen S., Frederickson C. A., and Brunden K. R. (1996) Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol. Aging 17, 781-787.
9. Cooper N. R. (1985) The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol 37, 151-166.
10. Cooper N. R. (1987) The complement system, in Basic and Clinical Immunology, Vol. 6 (Stiles D. P. and Terr A. I., eds), pp. 114-127. Appleton and Lange, Norwalk, Connecticut.
11. Cotman C. W. and Pike C. J. (1994) β-Amyloid and its contributions to neurodegeneration in Alzheimer disease, in Alzheimer Disease (Terry R. D., Katzman R., and Bick K. L., eds), pp. 305-315. Raven Press, New York.
12. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
13. Golan M. D., Burger R., and Loos M. (1982) Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J. Immunol. 129, 445-447.
14. Gorevic P. D., Castano E. M., Sarma R., and Frangione B. (1987) Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x ray diffraction pattern. Biochem. Biophys. Res. Commun. 147, 854-862.
15. Hanson D. C., Siegel R. C., and Schumaker V. N. (1985) Segmental flexibility of the C1q subcomponent of human complement and its possible role in the immune response. J. Biol. Chem. 260, 3576-3583.
16. Heinz H. P., Burger R., Golan M. D., and Loos M. (1984) Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q. J. Immunol. 132, 804-808.
17. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., and Butterfield D. A. (1994) A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl. Acad. Sci. USA 91, 3270-3274.
18. Hicks P. S., Saunero-Nava L., Du Clos T. W., and Mold C. (1992) Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149, 3689-3694.
19. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukjna N., and Ihara Y. (1994) Visualization of Aβ42 (43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45-53.
20. Jarrett J. T., Berger E. P., and Lansbury P. T. (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
21. Jiang H., Cooper B., Robey F. A., and Gewurz H. (1992a) DNA binds and activates complement via residues 14-26 of the human C1q A chain. J. Biol. Chem. 267, 25597-25601.
22. Jiang H., Robey F. A., and Gewurz H. (1992b) Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1qA chain. J. Exp. Med. 175, 1373-1379.
23. Jiang H., Burdick D., Glabe C. G., Cotman C. W., and Tenner A. J. (1994) β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol 152, 5050-5059.
24. Joseph R. and Han E. (1992) Amyloid β-protein fragment 25-35 causes activation of cytoplasmic calcium in neurons. Biochem. Biophys. Res. Commun. 184, 1441-1447.
25. Kirschner D. A., Inouye H., Duffy L. K., Sinclair A., Lind M., and Selkoe D. J. (1987) Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA 84, 6953-6957.
26. Koh J.-Y., Yang L. L., and Cotman C. W. (1990) β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533, 315-320.
27. Kozlowski M. R., Spanoyannis A., Manly S. P., Fidel S. A., and
28. Neve R. L. (1992) The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding. J. Neurosci. 12, 1679-1687.
29. Krumdieck R., Hook M., Rosenberg L. C., and Volanakis J. E. (1992) The proteoglycal decorin binds C1q and inhibits the activity of the C1 complex. J. Immunol. 149, 3695-3701.
30. Loo D. T., Copani A., Pike C. J., Whittemore E. R., Walencewicz A. J., and Cotman C. W. (1993) Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 90, 7951-7955.
31. Lorenzo A. and Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
32. Lue L.-F. and Rogers I. (1992) Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3, 308-313.
33. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249.
34. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydell R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
35. Mattson M. P., Tomaselli K. J., and Rydel R. E. (1993) Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res. 621, 35-49.
36. Miller D. L., Papayannopoulos I. A., Styles J., Bobin S. A., Lin Y. Y., Biemann K., and Iqbal K. (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 41-52.
37. Pepys M. B., Dash A. C., Markham R. E., Thomas H. C., Williams B. C, and Petrie A. (1978) Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin. Exp. Immunol. 32, 119-124.
38. Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
39. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
40. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995) Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
41. Rogers J., Schultz J., Brachova L., Lue L.-F., Webster S., Bradt B., Cooper N. R., and Moss D. E. (1992a) Complement activation and β-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143, 624-630.
42. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., and Lieberburg I. (1992b) Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 89, 10016-10020.
43. Rogers J., Webster S., Lue L.-F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., and McGeer P. (1996) Inflammation and Alzheimer's pathogenesis. Neurobiol. Aging 17, 681-686.
44. Roher A. E., Lowenson J. D., Clarke S., Woods A. S., Cotter R. J., Cowing E., and Ball M. J. (1993) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90, 10836-10840.
45. Rosenberg A. M., Prokopchuk P. A., and Lee J. S. (1988) The binding of native DNA to the collagen-like segment of C1q. J. Rheumatol. 15, 1091-1096.
46. Sabo S., Lambert M. P., Kessey K., Wade W., Krafft G., and Klein W. L. (1995) Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci. Lett. 184, 25-28.
47. Schumaker V. N., Poon P. H., Seegan G. W., and Smith C. A. (1981) Semi-flexible joint in the C1q subunit of the first component of human complement. J. Mol. Biol. 148, 191-197.
48. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham E. F., Wright S., Lieberburg I., Becker G. W., Brems D. N., and Li W. Y. (1994) Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45, 373-379.
49. Snyder S. W., Ladror U. S., Wade W. S., Wang G. T., Barrett L. W., Matayoshi E. D., Huffaker H. J., Krafft G. A., and Holzman T. F. (1994) Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 1216-1228.
50. Tagliavini F., Giaccone G., Frangione B., and Bugiani O. (1988) Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and non-demented individuals. Neurosci. Lett. 93, 191-196.
51. Tamaoka A., Kondo T., Odaka A., Sahara N., Sawamura N., Ozawa K., Suzuki N., Shoji S., and Mon H. (1994) Biochemical evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem. Biophys. Res. Commun. 205, 834-842.
52. Tomski S. J. and Murphy R. M. (1992) Kinetics of aggregation of synthetic β-amyloid peptides. Arch. Biochem. Biophys. 294, 630-638.
53. Ueda K., Fukui Y., and Kageyama H. (1994) Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res. 639, 240-244.
54. Webster S. and Rogers J. (1996) Relative efficacies amyloid β peptide (Aβ) binding proteins in Aβ aggregation. J. Neurosci. Res. 46, 58-66.
55. Webster S., O'Barr S., and Rogers J. (1994) Enhanced aggregation and β structure of amyloid β peptide after co-incubation with C1q. J. Neurosci. Res. 39, 448-456.
56. Webster S., Glabe C., and Rogers J. (1995) Multivalent binding of complement protein C1q to the amyloid β-peptide (Aβ) promotes the nucleation phase of Aβ aggregation. Biochem. Biophys. Res. Commun. 217, 869-875.
57. Wisniewski H. M. and Terry R. D. (1973) Reexamination of the pathogenesis of the senile plaque. Prog. Neuropathol. 11, 1-26.
58. Wisniewski H. M., Moretz R. C., and Lossinsky A. S. (1981) Evidence for induction of localized amyloid deposits and neuritic plaques by an infectious agent. Ann. Neurol. 10, 517-522.
59. Wood S. J., Maleef B., Hart T., and Wetzel R. (1996) Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ. J. Mol. Biol. 256, 870-877.
60. Yamaguchi H., Hirai S., Morimatu M., Shoji M., and Harigaya Y. (1988) Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol. 77, 113-119.
61. Yankner B. A., Duffy L. K., and Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid-β protein: reversal by tachykinin peptides. Science 250, 279-281.
62. Ying S.-C., Gewurz A. T., Jiang H., and Gewurz H. (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J. Immunol. 150, 169-176.
63. Younkin S. G. (1995) Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann. Neurol. 37, 287-288.